Background and methods: Gene therapy may offer a new tool for the treatment of renal cell carcinoma ( RCC ). We have tested a combination of cytotoxic and antiangiogenic gene therapy for wild -type orthotopic human RCC xenografts in nude mice using intratumoral adenovirus -mediated herpes simplex virus thymidine kinase ( HSV -tk ) and endostatin ( ES ) gene therapy. In vivo magnetic resonance imaging, morphometry, immunocytochemistry, and survival were used to evaluate the treatment effect. Adenovirus -mediated marker gene transfers ( GFP ) were used as controls. Results: In vivo transduction efficiency, measured using GFP gene transfer, was 27 ± 7%. The combination gene therapy with HSV -tk and ES adenoviruses resulted in a significant antitumor effect ( P < .01 ) compared to single HSV -tk ( n.s. ) or ES ( n.s. ). In the survival study, all tumors with single gene therapy using HSV -tk, ES, and marker gene adenoviruses showed progression in magnetic resonance imaging. In contrast, the majority of the tumors in the combination treatment group remained dormant or were eradicated ( 57% ). Survival of these mice equaled healthy nude mice, and was significantly prolonged ( P < .0001 ) compared to HSV -tk ( P < .028 ) and ES ( n.s. ) groups. Conclusions: It is concluded that the inhibition of angiogenesis using ES gene transfer together with the cytotoxic HSV -tk gene therapy results in a significantly improved treatment effect in RCC compared to the single gene treatments.
T he success of therapies for renal cell carcinoma (RCC ) depends greatly on the stage of the disease. Providing that the tumor is local, a curative result can be achieved with radical nephrectomy. 1 However, in a disseminated disease, the chances for complete response even with modern cancer management are poor. 2 -4 Gene therapy may offer a new tool for the treatment of RCC. So far, the majority of gene therapy studies for kidney tumors have involved modulation of immune response, 2, 5 and some of these applications, such as the use of interferona and interleukin -2, are already in clinical use. 6 Cytotoxic approaches, especially herpes simplex virus thymidine kinase ( HSV-tk ) and cytosine deaminase gene therapies, have been widely studied for many malignancies, 5,7 -9 but neither of them has been used in clinical trials for RCC. The inhibition of angiogenesis is also an actively studied antitumor approach. 10 -13 Once transduced with an HSV-tk gene, tumor cells become sensitive to ganciclovir (GCV ) treatment due to the ability of HSV-tk to catalyze the phosphorylation of GCV to a cytotoxic DNA analogue, which is further incorporated into DNA, leading to subsequent termination of DNA replication. 9, 14 Endostatin inhibits tumor angiogenesis by interfering at multiple levels of the growth factor signaling for endothelial cell proliferation, migration, and vessel formation. 10, 15, 16 Previously, we have shown a significant treatment effect in orthotopic human RCC (Caki-2 ) xenografts in a nude mouse model 17 using intratumoral HSV-tk gene therapy. Neither HSV-tk adenovirus in the absence of GCV, nor GCV coupled with an adenovirus containing a LacZ marker gene had any antitumor effect. 18 Given the high vascularity of human RCCs and the inability of HSV-tk monotherapy to eradicate the tumors, we decided to test a novel combination of cytotoxic and antiangiogenic gene therapy using intratumorally delivered HSV-tk and ES adenoviruses. It was found that the transduction efficiency, measured from GFP -transduced tumors, was 27± 7%. The combination therapy led to a massive shrinkage of the tumors ( P <.01) compared with single HSV-tk or ES treatment. During the survival study, all tumors in HSV-tk, ES, and marker gene groups showed progression in magnetic resonance imaging ( MRI ), whereas the majority of the tumors in the combination treatment group remained dormant. Survival time in the combination group was significantly prolonged ( P <.0001), and tumors were completely eradicated in 57% of mice treated with the combination therapy.
Materials and methods

Viral vectors
The HSV-tk adenovirus was produced as described. 19 For the production of ES adenovirus, a mammalian expression cassette with a c -myc -tagged rat endostatin cDNA was generated by PCR. The cassette also contained the mouse type XVIII collagen signal sequence 20 and had the following N -terminal sequence: MAPDPSRRLCLLLLLLLSCRLV-PASADHTHQ. To create a recombinant adenovirus expressing rat endostatin, the expression cassette was cloned into the pQBI -AdCMV5 -IRES -GFP vector (Quantum Biotechnologies, Montreal, Quebec, Canada ). The vector and the plasmid pJM17 ( Microbix Biosystems, Toronto, Ontario, Canada ) were then cotransfected into 293 cells, and recombinant adenovirus was isolated, amplified, and purified Overall test for differences of the groups Kruskal -Wallis ANOVA c 2 = 11.2, P = .011. *Six mice were used for marker gene studies; total n = 19 in this group. yAnimals selected for survival with MRI follow -up. zAnimals selected for survival, without MRI follow-up.
according to standard procedures. Thus, ES is a fusion gene construct containing also a GFP marker gene driven by IRES translation, and it is abbreviated as ES throughout the text. The control virus, ad -GFP, was purchased from Quantum Biotechnologies, and amplified and purified in the same way. Titers of the ES and GFP adenoviruses were determined by plaque assays on 293 cells. 21 
Cell lines
The human RCC Caki-2 cell line ( HTB -47; American Type Culture Collection, Rockville, MD, USA ) was used for renal subcapsule (RSC ) implantations. Cells were cultured in McCoy's 5A medium supplemented with 10% FBS and 1Â Pen -Strep. All cell culture chemicals were obtained from Life Technologies (Paisley, Scotland, UK ). For implantations, cells were harvested from subconfluent plates, washed with plain medium, counted, and resuspended in serum -free culture medium at a density of 35,000 cells/ L. The suspension was kept on ice until implantation. 17 The human glioma U251MG cell line ( Department of Pathology, Uppsala University, Uppsala, Sweden) was used for in vitro testing of the expression of the c-myc -tagged ES adenovirus using immunoblotting and immunocytochemistry as described. 21 Briefly, cells were grown in Ham's F10 medium supplemented with 10% FCS and 1Â Pen-Strep ( Life Technologies ). For immunoblotting, ES -transduced cells were trypsinized and solubilized on ice for 30 minutes in Trasylol buffer (Bayer, Leverkusen, Germany ). After removal of nuclei by centrifugation, equal amounts of proteins were run on 12% SDS -PAGE and blotted on a nitrocellulose membrane ( Protran; Schleicher and Schull, Dassel, Germany ). To detect c -myc -tagged ES, a mouse mAb 9E10 22 directed against a 10-amino -acid c-myc peptide sequence, followed by an HRP -conjugated antimouse IgG antibody and a chromogen ( Amersham, Piscataway, NJ ), was used. For immunocytochemistry, cells were plated on cover slips, followed by transduction on the next day with ES at a multiplicity of infection of 50. Forty -eight hours later, cells were fixed in 3% paraformaldehyde, permeabilized for 30 minutes in 0.1% Triton X -100, and incubated with a mouse anti -c -myc mAb, followed by incubation with a TRITC -conjugated antimouse IgG secondary antibody (Sigma, St. Louis, MO, USA ). To visualize c-myc and GFP signals in U251MG cells, cover slips were mounted on slides and cells were photographed with an Axiophot microscope (Zeiss, Gottingen, Germany ).
Nude mouse model
Six -to 8-week old Balb /cA -nu male nude mice ( M&B, Ry, Denmark ) were used. The mice were kept in a pathogen -free isolator unit. Food, water, and aspen wood chip bedding were autoclaved, and the mice received chow and water ad libitum. Tumors were generated as described previously. 17 Briefly, the mice were anesthesized, the left kidney was exposed through a flank incision, and 5Â10 5 Caki -2 cells were implanted into the RSC. The kidney was then replaced into the body cavity, and peritoneum and skin incisions were closed with sutures. All animal protocols were approved by the Experimental Animal Committee of the University of Kuopio.
Imaging
To confirm the presence of tumors and to evaluate the treatment effect, MRI was performed using a 9.4-T vertical bore magnet ( Oxford Instruments, Oxford, UK ), equipped with actively shielded field gradients ( Magnex Scientific, Abdington, UK ) interfaced to an SMIS console (Surrey Medical Imaging Systems, Guildford, UK ). A surface coil ( diameter of 28 mm ) was used for signal transmission and reception. Mice were anesthesized as described above, fixed to a holder, and multislice T 2 -weighted images were taken using the following parameters: repetition time = 2000 milliseconds, echo time =35 milliseconds, field of view = 40 mm, imaging matrix 256Â128 ( zerofilled to 256Â256 ), 4 averages, and 20 slices with the slice thickness of 1 mm ( no separation ) in transverse orientation. Tumor volumes were measured manually from MRI images with Image Display ( Surrey Medical Imaging Systems ) software. The volumes (mm 3 ) were calculated by measuring the area of the tumor (mm 2 ) in each slice and multiplying the summation of the areas by the slice thickness. 17 For the imaging schedule, see Figure 1 .
Preparation of tissue specimens for histological studies
The kidneys and tumor samples were excised and immersed in 4% paraformaldehyde for 4 -6 hours followed by Cancer Gene Therapy overnight immersion in 15% sucrose. 23 The kidneys, liver, abdominal cavity, lungs, and brains were assessed macroscopically for metastases during autopsy, and samples from these tissues were harvested and fixed as described above for microscopic examination (Olympus AX70 Microscope; Olympus, Tokyo, Japan ). The specimens were embedded in paraffin, and sections ( 5 m ) were analyzed with hematoxylin -eosin, Ki -67 (08-0192; Zymed, South San Francisco, CA, USA ), macrophage ( a rabbit antiserum, AIA31240; Accurate Chemical and Scientific, Westbury, Figure 3 Histological and immunocytochemical characteristics of the treatment effect. A: A frozen section from a wild -type Caki -2 tumor transduced intratumorally with GFP shows green transgene expression throughout the tumor on day 7 posttransduction ( group IV ). The areas that appear negative for the GFP signal are cystic structures within the tumor. B: A frozen section from a tumor transduced with ES ( also containing GFP ) still shows some areas of high GFP gene transfer efficiency at time point B ( group I ). C: A treated tumor ( group I ) shows necrotic areas ( white arrow ) and dense macrophage infiltrations ( cells with brown -colored cytoplasmic inclusions, open arrow ) located mainly in a fibrous scar. Intact kidney parenchyma between the arrowheads. Hematoxylin -eosin staining. D: High rate of apoptosis ( green nuclear color ), located mainly in fibro -septas ( group I ). TUNEL staining. E: A negative control for the TUNEL staining shown in ( D ). F: A Ki -67 staining shows sporadic areas of active proliferation ( red -stained nuclei, group I ). AEC chromogen and hematoxylin counterstaining. G: Endothelial cell -specific immunostaining ( CD31 ) ( group I ) shows capillary structures ( black arrowheads ) that are located mainly in the tumor and intact kidney parenchyma ( between the arrowheads ) junction. DAB chromogen and hematoxylin counterstaining. H: TUNEL staining shows apoptosis in several endothelial cells in a residual tumor ( white arrowheads, group I ). I: Endothelial immunostaining ( CD31 ) of a serial section of the same tumor as in ( H ). J: A kidney of a mouse ( group I ) at the end of the survival period ( 45 weeks ). A thin fibrous scar replaces the eradicated tumor, whose volume prior to HSV -tk and ES gene therapy was 133 mm NY, USA ), apoptosis ( Apoptag 1 Plus Fluorescein In Situ Apoptosis Detection Kit S7111; Intergren, Oxford, UK ), and endothelial cell (CD -31 PECAM 09151A; BD Pharmingen, San Diego, CA, USA ) stainings. Chromogens AEC ( 00-1111; Zymed ) and DAB ( 00-2020; Zymed ) were used for signal detection. Class -and species-matched irrelevant antibodies and incubations, where primary antibodies were omitted, were used as controls. 17 Also, tumor samples and selected tissues from each animal were embedded in OCT compound (Miles Scientific, Naperville, IL, USA ) and processed for frozen sections. 18, 24 In vivo transduction efficiency was examined from frozen sections by calculating GFP -positive cells ( percent of all cells ) 7 and 20 days posttransduction using four sections per tumor 100 m apart from each other, and 10 fields per section with 40 -fold magnification, covering systematically the central and peripheral areas of each tumor.
Gene therapy
A total of 51 nude mice were randomly divided into four groups ( see Table 1 and Fig 1 ) . MRI was performed at time point A to verify the size of the tumors. For transductions, mice were reoperated as described above; the tumors were identified with an operating microscope and the genes were delivered using intratumoral injection (25 -L Hamilton Microlitersyringe 2 , RN 1702; 27-gauge needle, RN 207427 /00; Hamilton Bonaduz, Bonaduz, Switzerland ). Group I ( Fig 1A; n= 12 ) received both HSV-tk and ES, group II ( Fig 1B; n= 10 ) received ES, group III ( Fig 1A; n = 10) received HSV-tk, and group IV (Fig 1B; n =19 ) received marker gene transfers. The volume of adenovirus injection was 20 L per tumor in group I, and 15 L per tumor in groups II -IV. The total amount of virus in all groups was 10 8 pfu /tumor. Tisseel 1 Duo Quick tissue glue ( Immuno, Wien, Austria ) was applied at the injection site to prevent the leakage of the virus, and peritoneum and skin incisions were closed with sutures. Groups I and III ( Fig 1A ) received intraperitoneal GCV ( Cymevene 1 , 500 mg; F. Hoffman -La Roche, Basel, Switzerland ) injections 50 mg /kg/ day for 14 days twice a day beginning on day 5 posttransduction. MRI was performed to assess the response to the treatment as shown in Figure 1 . For evaluation of the transduction efficiency, six mice from group IV were sacrificed on days 7 (n =4 ) and 20 (time point B, n= 2) posttransduction for the detection of GFP signal.
Randomly selected mice were used for the survival study, and the rest were sacrificed for histological studies. Four to seven mice from each survival group were imaged with MRI at 4 (time point C ) and 16 (time point D ) weeks after time point B for detecting relapses. Autopsy was performed and histological samples were harvested at the time of death from every mouse.
Statistical methods
Cavalier's method 25 was used to calculate tumor volumes from MRI. Relative volumes (pretreatment / posttreatment ratio) were used. The measurements were carried out blindly by two observers. Kruskal -Wallis ANOVA was used for the Cancer Gene Therapy HSV -tk and endostatin gene therapy for renal cell carcinoma KJ Pulkkanen et al statistical analysis of the differences between the treatment results followed by a nonparametric multiple comparison test with a control group (group IV versus other groups ). 26 Kaplan-Meier plots and log rank test were used for the analysis of survival data. Values are mean ± SD.
Results
Efficiency of the gene therapy
The implantations of Caki -2 cells into RSC generated in 4 weeks grades II and III 27 cystic -papillary kidney carcinomas in left kidneys of the nude mice. 18 Immunoblotting and immunocytochemistry of in vitro ES -transduced U251MG cells showed the presence of the c-myc tag in the cell lysate and culture medium, and strong intracellular expression of the c -myc -tagged ES, respectively (Fig 2, A and B ) , thus confirming the functionality of the vector. The in vivo gene transfer efficiency in the Caki -2 tumors was 27 ±7% on day 7 posttransduction ( Fig 3A ) . At time point B, 20 days posttransduction, the number of GFP -positive cells in GFPand ES -transduced (containing also GFP ) tumors had declined to <1%, although a few highly transduced areas were still observed as shown in Figure 3B .
The efficacy of the combination of the HSV-tk and ES ( group I) was superior compared to the other groups ( Table  1 ). The relative tumor volumes, measured from MRI (Fig 4 ) after the primary treatment period at time point B, were as follows: group I, 0.48 ± 0.51 ( P <.01 ) ( Fig 4, A and B ) ; group II, 1.11 ± 1.04 (n.s. ); group III, 1.21 ± 0.86 (n.s. ) ( Fig   4, E and F ) ; and group IV, 2.68 ± 3.51 ( Fig 4, I and J) . Looking at time point B MRI (Table 1 ) , there were only two modestly progressed tumors in group I, whereas all other tumors were regressed to a fraction compared to time point A. Groups II and III were quite similar to each other; about half of the tumors had regressed in each group. With one exception, all tumors in control group IV showed progression.
A subset of animals from groups I-III was sacrificed at time point B. Hematoxylin-eosin stainings showed necrosis in the treated areas in groups I ( Fig 3C ) , II, and III. Fibrous scar formation was detected in group I tumors, indicating an active regeneration process in the place of the destroyed tumors ( Fig 3C ) . Apoptosis was higher in groups I and II, varying from 10% to 15% of all cells. A high rate of apoptosis, up to 30%, was detected in fibrous areas of the destroyed tumors ( Fig 3, D and E ) . In group III, the apoptosis rate varied from 3% to 5%, and in group IV it was < 1% ( data not shown ). Ki -67 stainings showed 5.5 ± 6%, 7.0± 4.5%, and 3.5 ± 3% proliferation index in groups I (Fig  3F) , II, and III, respectively. Dense macrophage infiltrations, located mainly in fibro-septas, were seen in all reduced tumors in group I, and to a lesser degree in groups II and III ( Fig 3C ) . Endothelial cell staining revealed moderate capillary density scattered in fibro -septas predominantly near the junction of the tumors and kidney parenchyma ( Fig  3G ) . Endothelial cells in fibro -septal capillary structures showed strong apoptosis, especially in group I ( Fig 3, H and  I ). The histology of liver of the treated animals appeared normal in hematoxylin -eosin stainings. 
Survival
Survival data are presented in Table 2 and Figures 4 and 5 . The mean survival times for different study groups were as follows: group I, 41± 8 (P < .0001 ); group II, 26 ± 5 ( n.s. ); group III, 30 ± 5 (P < .028); and group IV, 23 ± 6 weeks.
MRI showed progression or relapse in all tumors in groups II -IV during survival. In contrast, only one tumor in group I relapsed, whereas the other tumors remained dormant. The lifespan of these mice was similar to healthy nude mice. 28 The mean tumor volumes in groups II, III, and IV at the time of death were 43-, 12-, 26-fold, respectively, compared with group I (P < .01). The tumor-bearing mice in groups II -IV suffered from ascites and wasting, and peritoneal carcinosis nodules were present in a subset of these mice.
In group I, four mice out of seven were tumor-free at autopsy. Histology showed only scar formation in the treated area (Fig 3, J and K ) . Ki -67 did not show any proliferation in the scar ( Fig 3L ) . Macrophage infiltrates were observed at the boundary of the scar and intact kidney ( Fig 3, J and K ) . Few capillary structures were seen in the scar tissue ( Fig  3K ) . No metastases were detected in these mice. Looking at the follow -up MRI, all mice in group I had residual tumors in the left kidneys at time point B, and in the later measurements, these residuals showed further regression. In the late survival MRI, it was not possible to distinguish whether these lesions were residuals or fibrous scar. However, histology at the end of the survival study provided clear evidence that the eradication of the tumors had been achieved.
Discussion
The combination of cytotoxic and antiangiogenic gene therapy is a promising new approach for the treatment of RCC. We achieved a significant in vivo antitumor response in orthotopic human RCC in a nude mouse model using the combination of HSV-tk and ES ( group I ) gene therapy. Compared to the other study groups, both the primary antitumor response and the prolongation of the survival time were improved. The majority of the tumors in group I mice either remained dormant or were completely eradicated during the survival period. The lifespan of these mice was similar to healthy nude mice. 28 Previously, cytotoxic gene therapy has been tested for human RCC in a subcutaneous nude mouse model 5 using cytosine deaminase and HSV-tk gene therapy. In this study, HSV-tk, coupled with acyclovir, failed to demonstrate any antitumor effect. The discrepancy between this and our previous study, where HSV-tk monotherapy was used, 18 may be due to the fact that tumor cells in our model express gap junctions and display a bystander effect, 17, 29 allowing more efficient action of GCV. 30 Also, GCV is a more potent replication terminator than acyclovir. 31 However, albeit the survival benefit in the present study after the HSV-tk monotherapy, the initial antitumor response at time point B did not reach statistical significance. Regarding the use of endostatin for the treatment of RCC, endostatin gene transfer, either intramuscular 32 or intratumoral, 33 has resulted in a significant tumor growth arrest in subcutaneous murine RCC models, although negative results of the efficacy of the endostatin treatment in various types of cancers have also been reported. 34, 35 As adenovirus is the most efficient gene transfer vector available today, it was used for the gene delivery in the present study. However, adenoviruses are known to generate only a transient treatment effect, 36 and this raises questions about the mechanism of dormancy 10 and eradication of tumors in group I especially because the majority of the tumor cells expressing the transgene should be destroyed during the GCV treatment. Also, what mechanism could explain the strong primary response in the combination treatment group over the single gene transductions, and why did the ES -transduced tumors, which first shrank, later relapse? Sustained dormancy and eradication of the tumors in group I suggest that the cytotoxicity of the HSV-tk, together with the additive antiangiogenic effect of ES, efficiently prevented regrowth of the residual tumor cells. Although local gene transfer was used, marker gene studies in this animal model showed that a small number of adenoviruses escape into the circulation, leading to transduction of liver. 18 As the potency of endostatin is well established, 37 it is possible that even a low -level transduction of liver by ES can result in a sufficient and sustained production of endostatin into circulation to maintain tumor dormancy. Indeed, we detected the presence of endostatin in the livers of intratumorally ES -transduced mice, but not in the controls, on day 7 after the transduction using genomic PCR ( data not shown ). Recently, Kuo et al 38 reported that tail vein injections of recombinant adenoviruses encoding endostatin and angiostatin produced only a modest growth inhibition in a few subcutaneous murine tumor models. Also, the levels of systemic endostatin required for antitumor effect have displayed great variations ranging from low 32 to high concentrations. 39 A direct comparison of these findings with the present study is difficult due to the differences between the tumor models, and therapeutic interventions.
In addition to cytotoxicity and inhibition of tumor angiogenesis, other factors may have also contributed to the effectiveness of the combination therapy. Although cytotoxic T-cell response in nude mice is absent, 30 macrophage -, natural killer -, and lymphokine -activated killer Figure 5 Kaplan -Meyer plots and log rank test for the survival groups. Statistical significance is as follows: group I ( combination of HSV -tk and ES ), P < .0001; group II ( ES ), n.s.; group III ( HSV -tk ), P < .028.
cell -dependent antitumor effects may still occur. 40 The pronounced and long -lasting accumulation of macrophages in group I tumors suggests that the combination of cytotoxicity and inhibition of tumor angiogenesis gave rise to immune response that significantly enhanced the in vivo bystander effect. One of the suggested mechanisms of the action of endostatin is apoptotic cell death, 41 and TUNEL staining showed clear apoptosis in the endothelium of the tumor vessels in group I. The results of the TUNEL assay must be evaluated cautiously especially in mouse tissues. 42 However, we have not detected false -positive apoptosis in endothelial cells of healthy nude mouse kidneys. The suggested toxicity of GFP, 43, 44 contained in ES, as a cause for the antitumoral effect can be ruled out because of the lack of tumor regression and similar length of survival in GFPtreated mice compared to the untreated or LacZ -transfected mice. 17, 18 We conclude that the inhibition of angiogenesis using ES gene transfer, together with the cytotoxic HSV-tk gene therapy, resulted in a significant antitumor effect compared to the single gene -based therapies in RCC. Also, the survival time of the mice in the combination therapy group was similar to the healthy nude mice, and a complete tumor eradication occurred in 57% of these mice. Given the facts that intratumoral injections are applicable to tumors that can often be easily resected, and that nephrectomy is an established and efficient treatment for primary RCC, the clinical value of intratumorally delivered gene therapy is limited. However, the results warrant further development of the combination gene therapy, and suggest that this approach, directed towards systemic efficiency, could be used as an additional treatment for human RCC.
